LEX Diagnostics
Andrew Anyakwo serves as the Director of Biology at LEX Diagnostics. Previously, Andrew worked as the Principal Scientist at QuantuMDx Group Limited and as an Assay Development Scientist II at genedrive. With a background in microbiology and biotechnology, Andrew has held various research and development roles at companies such as Mastgroup and Trinitron Biotech Limited. Andrew also has experience in quality control from their time as an Industrial Trainee at The Coca-Cola Company. Overall, Andrew is a highly experienced professional in the field of biology and has a strong academic background with a PhD in Clinical Microbiology.
LEX Diagnostics
LEX Diagnostics is a medical device company that specializes in molecular diagnostics for primary care. Having solved the PCR cost problem, LEX focuses tightly on nasal and oral samples, and on viral pathogens, to avoid the other high-cost elements of traditional molecular diagnostic products. LEX Diagnostics is a spin-out from TTP plc, atechnology development company in the life science and medical device sector. The origins of the LEX technology lie in an internal R&D project to reduce the time it takes to get a result from a PCR test. It formed a company when it became clear the solution also reduced the cost and size of any diagnostic device using it.LEX Diagnostics was founded in 2020 and is based in Melbourn, United Kingdom.